Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dutasteride - GlaxoSmithKline

Drug Profile

Dutasteride - GlaxoSmithKline

Alternative Names: Avodart; Avolve; Duagen; GG 745; GI 198745; GI-198745X

Latest Information Update: 25 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiandrogens; Antineoplastics; Azasteroids; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Preregistration Submission Withdrawal Prostate cancer; Prostatic intraepithelial neoplasia
  • No development reported Alopecia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Jan 2018 No development reported - Phase-III for Alopecia in Singapore, Chile, Taiwan, Hong Kong, Japan, South Korea (PO)
  • 03 Mar 2017 GlaxoSmithKline completes a phase III trial in Benign prostatic hyperplasia (Combination therapy) in China, Japan, South Korea and Taiwan (NCT02058368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top